Targeted Protein Degradation: Designed to destroy
The sector is entering a decisive phase in 2026. Multiple late-stage clinical programmes are approaching potential regulatory milestones, big pharma companies are expanding partnerships, and investors increasingly view induced proximity technologies as a …